Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
(23 intermediate revisions by 3 users not shown)
Line 7: Line 7:
  
 
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers 2023-03-28]]
 
*[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers 2023-03-28]]
−
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
+
*[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19]]
  
 
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists
 
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists
Line 20: Line 20:
 
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]
 
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]]
 
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 +
 +
*[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf | US Shear Wave Speed for Liver Fibrosis 2024-01-15]]
 +
::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E 2023-12-28]]
 +
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]]
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
Line 26: Line 30:
 
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]
 
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]]
  
−
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification 2012-08-08]]
+
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification (V.1) 2012-08-08]]
  
 
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]
 
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]]
Line 39: Line 43:
 
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
 
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
  
−
*[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis 2022-04-25]]
+
*[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf | US Volume Blood Flow Profile, Consensus version 2024-01-05]]
−
::*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Checklists - US SWS Appendix E 2022-04-25]]
 
−
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]]
 
  
−
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
+
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]]
  
−
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']
+
*[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06]]
−
 
 
−
*[[Media:QIBA MRI-Based PDFF of the Liver_Profile-Stage 1-Public Comment.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-09-08]] (BC review and vote underway)
 
−
 
 
−
*[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE Quantification 2020-10-12]] (comments '''closed''' on March 10, 2021)
 
  
 +
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
 
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)
 
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017)
  
Line 62: Line 61:
  
  
−
'''[[Media:QIBA Profiles and Clinical Applications-v12April2023.xlsx|QIBA Profiles and Clinical Applications]]'''
+
'''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]'''
  
 
   
 
   

Revision as of 17:36, 17 January 2024

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.

Tools to aid Biomarker Committees in collating these comments:


QIBA Profiles and Clinical Applications


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also
Retrieved from "https://qibawiki.rsna.org/index.php?title=Profiles&oldid=19584"